Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1315 results about "Single chain" patented technology

Recombinant botulinum toxin and preparation method thereof

ActiveCN119859174ANervous disorderPeptide/protein ingredientsHeavy chainBotulinum toxin type
The invention relates to the technical field of a preparation method of a type A recombinant botulinum toxin, in particular to a type A botulinum toxin obtained by adopting a gene recombination technology, and the amino acid sequence of the type A botulinum toxin is consistent with the sequence of the type A botulinum toxin prepared by extracting and purifying a wild strain Clostridium botulinum. According to the technical scheme, the single-chain protein of the botulinum toxin A sequentially comprises a botulinum toxin A light chain or a modified botulinum toxin A light chain, a connecting region and a botulinum toxin A heavy chain. According to the scheme, the high-quality recombinant botulinum toxin A is obtained after the single-chain protein is subjected to fermentation, crude purification, enzyme digestion and fine purification. According to the technical scheme, the problems of complex process, long period, high safety risk and the like in the existing process for preparing the botulinum toxin A from the wild bacterial strain clostridium botulinum can be solved, and meanwhile, the problem that the amino acid sequence consistent with that of the botulinum toxin A prepared from the wild bacterial strain clostridium botulinum cannot be obtained through the existing gene recombination technology is solved.
Owner:LEPU JIANTANG PHARMACEUTICAL (CHONGQING) CO LTD

CA9-targeted chimeric antigen receptor and application thereof

The invention discloses a CA9-targeted chimeric antigen receptor and application thereof, and belongs to the technical field of biological medicines. The CA9 targeting chimeric antigen receptor provided by the invention comprises a CD8 alpha leading signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane structural domain and a CD3 zeta intracellular costimulatory signal transduction structural domain. According to the invention, an anti-CA9 single-chain variable fragment is used as an antigen binding structural domain to construct a chimeric antigen receptor (CAR) molecule, the macrophage expressing the anti-CA9CAR can realize specific targeting and phagocytosis killing of CA9 positive kidney cancer cells, and the constructed lipid nanoparticle delivery system can effectively transfer a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the CA9 positive kidney cancer cells can be effectively targeted and killed. The constructed hydrogel-liposome combined drug delivery system has the performance of relieving toxic and side effects, controllable release and hemostasis.
Owner:LIFE VALLEY (QINGDAO) HEALTH TECHNOLOGY CO LTD

Bispecific chimeric antigen receptors targeting CD20 and BCMA

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Owner:ABELZETA INC

CRISPR / dCas9-SunTag mediated RBM25 controllable activation system and application thereof in ischemic heart failure myocardial repair

The invention relates to the field of gene therapy, in particular to an RBM25 gene epigenetics activation technology based on a CRISPR / dCas9-SunTag system and application of the RBM25 gene epigenetics activation technology in ischemic heart failure treatment, the RBM25 gene epigenetics activation technology comprises the following steps: (a) protein containing inactivated Cas9 (dCas9) fused with a plurality of GCN4 peptide repetitive sequences, the number of the GCN4 peptide repetitive sequences is 8-12, and the dCas9 contains D10A and H840A double mutations; (b) a protein containing fusion of an anti-GCN4 single-chain antibody fragment (scFv) and a TET1 catalytic structural domain; (c) at least one gRNA of a target RBM25 gene promoter region, wherein a target sequence of the gRNA is selected from a sequence as shown in SEQ ID NO: 1-3; and (d) a lipid nanoparticle (LNP) system for delivery of said (a), (b), and (c).
Owner:LANZHOU UNIV SECOND HOSPITAL

Biological preparation for improving quality of weever and application

The invention relates to a biological preparation for improving quality of weever, the biological preparation comprises an injection and an edible agent, the injection comprises chemically modified chemically synthesized single-stranded small RNA, Rev-erbalpha protein and Per1 protein, and the edible agent comprises Clock core peptide 1, Clock core peptide 2 and taurine. Skeletal muscle development, liver lipid metabolism and generation of cell inflammatory factors of the weever are influenced by adding and injecting the feed, so that the quality of the weever is improved, intramuscular fat deposition is promoted, the taste and flavor of fish meat are improved, the energy reserve of the weever can be improved, and the culture cycle is shortened. The improvement of cell inflammatory factors shows that the disease resistance of the weever is improved, the survival rate in the breeding process is further improved, and the use amount of antibiotics is reduced. The method provides an important theoretical basis for improving fish meat quality in China and promoting high-quality, efficient and healthy development of aquaculture, and has a wide market prospect.
Owner:CHANGSHA UNIVERSITY

Immunity-inducing agent and pharmaceutical composition containing same

Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide / peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.
Owner:UNIVERSITY OF KITAKYUSHU +1

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
Owner:BIOVERATIV THERAPEUTICS INC

Artificial antigen presenting cell for efficiently preparing chimeric antigen receptor T cell as well as construction and application of artificial antigen presenting cell

The invention discloses an artificial antigen presenting cell for efficiently preparing a chimeric antigen receptor T cell (CAR-T) and a construction method of the artificial antigen presenting cell, and belongs to the field of cell therapy and immunotherapy, the artificial antigen presenting cell takes a K562 cell as a platform, an anti-CD3 single-chain antibody, an anti-CD28 single-chain antibody, a membrane binding type cell factor and a costimulatory ligand are stably expressed through genetic engineering, and the chimeric antigen receptor T cell (CAR-T) is obtained. And the local concentration of the anti-CD3 antibody is improved by adopting an HOTag3 tool. The multi-signal integration strategy obviously enhances the activation and proliferation capacity of the T cells, promotes the CAR-T cells to maintain a low differentiation state, and endows the CAR-T cells with excellent anti-tumor activity and durability. The artificial antigen presenting cell provides a novel efficient tool for the field of cellular immunotherapy, and is expected to promote development of more efficient and safer CAR-T therapy to cope with challenges of various malignant tumors.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI +1

Preparation of human CD56 immune bacteriophage display antibody library

The invention discloses preparation of a human CD56 immune phage display antibody library, which comprises the following steps: S1, animal immunization: expressing recombinant hCD56 protein in escherichia coli, then immunizing a Balb / c mouse, and detecting immune titer; s2, splenocyte preparation: extracting RNA (Ribonucleic Acid) of immune mouse spleen cells, and performing reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid); s3, preparation of an initial bacteriophage display library: amplifying a heavy chain variable region and a light chain variable region by using a PCR technology, and then assembling to form scFv; constructing scFv phagocytids, electrically transforming the scFv phagocytids into TG1 competent cells, and constructing a bacterial library; s4, constructing a phage single-chain library of the hCD56: infecting the bacterial library by using a helper phage M13K07, and constructing a phage single-chain antibody library; and S5, elutriation and screening of a phage library: specifically enriching a phage single-chain antibody library, screening positive clones from the phage single-chain antibody library, and determining a sequence. According to the invention, the human hCD56 antibody scFv sequence fragment can be screened out, and the research and development period is shortened.
Owner:IPHASE THERAPEUTICS LTD

CAR-NK cell for knocking out KIR2DL5 targeting HER2, preparation method and application thereof

The invention provides a CAR-NK cell for knocking out KIR2DL5 targeting HER2 as well as a preparation method and application of the CAR-NK cell, and belongs to the technical field of genetic engineering.The CAR-NK cell is obtained by adopting a chimeric antigen receptor with HER2 as a target spot to infect an NK cell and then knocking out a KIR2DL5 gene; the chimeric antigen receptor taking the HER2 as the target spot comprises an HER2 single-chain antibody; the nucleic acid artificial sequence of the HER2 single-chain antibody is as shown in SEQ ID NO. 2. According to the application disclosed by the invention, the interaction of KIR2DL5-PVR is blocked by knocking out NK cell immune checkpoints, so that tumor immune escape is avoided, and the activity of killing tumor cells by CAR-NK cells is remarkably enhanced; according to the invention, by optimizing the nucleic acid artificial sequence of HER2, the secretion ability of CAR-NK cell factors, the tumor killing efficiency and the in-vivo inhibition effect on tumors can be improved.
Owner:SHANGHAI XINGRUIYIDA BIOTECHNOLOGY CO LTD

Recombinant fusion protein of human lambda light-chain single-chain antibody, DNA (deoxyribonucleic acid) molecule, library building method and application

The invention discloses a recombinant fusion protein of a human lambda light-chain single-chain antibody, a DNA (deoxyribonucleic acid) molecule, a library building method and application, and the recombinant fusion protein of the human lambda light-chain single-chain antibody is the recombinant fusion protein formed by connecting the human lambda light-chain single-chain antibody, phage Piii protein and luciferase, the amino acid sequence of the recombinant fusion protein of the human lambda light-chain single-chain antibody is shown as SEQ ID NO: 5, the recombinant fusion protein library of the human lambda light-chain single-chain antibody has large capacity, the established single-chain antibody TG1 library is more than 1 * 10 < 9 > cfu / mL, positive clones capable of being combined with ligands can be screened and enriched for multiple rounds, and the recombinant fusion protein library has the characteristics of high sensitivity, high signal-to-noise ratio and the like.
Owner:SHENZHEN LONGHUA DISTRICT PEOPLES HOSPITAL

Recyclable biochip stationary phase as well as preparation method and application thereof

The invention discloses a recyclable biochip stationary phase as well as a preparation method and application thereof, and belongs to the field of biochips. The preparation method of the biochip stationary phase comprises the following steps: (1) activating a glass slide by adopting plasma, and then putting the glass slide into a silane coupling agent solution to react, so that a silane coupling agent is covalently bound with the glass slide to obtain a functionally modified biochip; and (2) combining the 5'end modified single chain oligo with the functionally modified biochip to obtain the biochip stationary phase. The biochip stationary phase disclosed by the invention is low in cost, excellent in physicochemical property, good in stability and tolerance and capable of adapting to a complex environment; more importantly, the method can be recycled, the resource utilization rate is increased, the pollution is reduced, and the method has huge application potential in the leading technical field of DNA synthesis by an enzyme method and the like.
Owner:TIANJIN ZHONGHE GENE TECH CO LTD +1

Hybridoma cell strain 1D6 as well as monoclonal antibody and application thereof

The invention discloses a hybridoma cell strain 1D6 as well as a monoclonal antibody and application thereof. The invention also discloses an application of the monoclonal antibody for resisting the Tilletia foetida in the detection of teliospore of the Tilletia foetida. The invention also discloses a single base sequence DNA single chain modified Tilletia foetida monoclonal antibody. The invention also discloses a detection kit. The monoclonal antibody as well as the marker and the kit thereof show high specific recognition capability on Tilletia foetida. The method for detecting the single base by mass spectrometry has a signal amplification effect and is simple and convenient in detection operation, so that the sensitivity and the detection efficiency of the method are remarkably improved. With the progress and continuous popularization and application of the mass spectrum technology, the technology has wide application potential and prospect.
Owner:NANJING PRODUCT QUALITY SUPERVISION & INSPECTION INSTITUTE (NANJING QUALITY DEVELOPMENT & ADVANCED TECHNOLOGY APPLICATION RESEARCH INSTITUTE)

RO52 targeting antibody or antigen binding fragments thereof for use in treating cancer

Provided herein are methods of treating a cancer in a subject, wherein the cancer expresses a Ro52 antigen, comprising administering an anti-Ro52 binding agent to the subject, thereby treating the cancer in the subject. In some embodiments, the Ro52 antigen is expressed on a cancer cell surface. In some embodiments, the anti-Ro52 binding agent comprises a Fab, Fab', F(ab')2, Fahl-SH, Fv, diabody, linear antibody or single-chain variable fragment (scFv). In some embodiments, the anti-Ro52 binding agent is a humanized or chimeric antibody. In some embodiments, the anti-Ro52 binding agent is conjugated to a therapeutic agent.
Owner:JOHNS HOPKINS UNIVERSITY

Double-target chimeric antigen receptor co-expressing CD47 and IL-15, CAR-T cell and application of CAR-T cell

The invention discloses a double-target chimeric antigen receptor for co-expression of CD47 and IL-15, a CAR-T cell and application of the CAR-T cell, and belongs to the technical field of genetic engineering, the double-target chimeric antigen receptor comprises a single-chain antibody scFv-EGFRv III, a single-chain antibody scFv-VEGF, CD47 and IL-15; the nucleotide artificial sequence of the single-chain antibody scFv-EGFRv III is as shown in SEQ ID NO. 6; the nucleotide artificial sequence of the single-chain antibody scFv-VEGF is as shown in SEQ ID NO. 9. According to the application disclosed by the invention, by performing sequence optimization on targets EGFRvIII and VEGF, the anti-tumor effect of CAR-T cells in glioblastoma can be improved, and by integrating immune checkpoint molecules CD47 and interleukin-15, the immunosuppression function of a CD47-SIRP alpha signal channel can be locally exerted.
Owner:SHANGHAI XINGRUIYIDA BIOTECHNOLOGY CO LTD

NRP1-targeting single-chain antibody, CAR-T cell and application of CAR-T cell in fibrosis treatment

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a single-chain antibody targeting NRP1, a CAR-T cell and application of the single-chain antibody and the CAR-T cell in fibrosis treatment. Four types of high-affinity single-chain antibodies targeting mouse NRP1 antigens are obtained by immunizing mice, the single-chain antibodies are applied to second-generation CAR, T cells of mouse spleen sources are infected after virus packaging, and CAR-T cells are constructed. The CAR-T cells of the targeted NRP1 can be used for effectively killing NRP1 positive cells. In-vivo experiments show that the CAR-T cells can inhibit the growth of NRP1 positive tumor cells. The CAR-T cell can improve the mouse liver fibrosis condition, collagen in the mouse liver is reduced through treatment, and the molecular level of fibrosis markers SMA and NRP1 is reduced, it is indicated that the CAR-T cell recognizes and eliminates activated HSCs through targeting NRP1, and the fibrosis degree is reduced.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Pentavalent phosphorylcholine ligand as well as preparation method and application thereof

The invention belongs to the technical field of biological materials, and particularly relates to a pentavalent phosphorylcholine ligand as well as a preparation method and application thereof. The pentavalent phosphorylcholine ligand comprises a central chain which is annular; the complementary chain and the central chain are assembled to form a DNA skeleton in which single chains and double chains are alternately arranged, and the secondary structure of the DNA skeleton is a regular pentagon; the double chains are rigid double chains, and the connecting part between the rigid double chains is a flexible short chain; the tail end of the complementary chain comprises a phosphorylcholine ligand and a small molecule part, and the phosphorylcholine ligand is connected with the DNA skeleton through the small molecule part. The invention also provides a preparation method of the pentavalent phosphorylcholine ligand. The pentavalent phosphorylcholine ligand is formed by assembling single-stranded nucleic acids with nucleotide sequences as shown in SEQ ID No.1 and SEQ ID No.2. The invention also provides a preparation method of the pentavalent phosphorylcholine ligand. The invention solves the problem of weak binding capacity of monovalent phosphorylcholine and C-reactive protein, and can be applied to detection of C-reactive protein in clinical samples related to infection, inflammation and cardiovascular diseases.
Owner:SOUTHWEST UNIV

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.
Owner:JUNO THERAPEUTICS INC +1

Nanoparticles for generating CAR-T in vivo and application thereof

The invention provides nano-particles for generating CAR-T in vivo and application of the nano-particles, and belongs to the technical field of medical preparations. The nanoparticles are nanoparticles which are coupled with a CD7 antibody and entrapped with mRNA (messenger Ribonucleic Acid); the mRNA is obtained by transcription of a target gene; the target gene comprises a TROP2 single-chain antibody; the nucleotide sequence of the TROP2 single-chain antibody is as shown in SEQ ID NO: 1. The nucleotide sequence of the TROP2 single-chain antibody is optimized, the CAR containing the TROP2 single-chain antibody is constructed, then the CAR is transcribed to obtain mRNA, LNP entrapped with mRNA is prepared, then the CD7 antibody subjected to amino acid sequence optimization is adopted to be coupled with the LNP entrapped with mRNA, the transfection efficiency of the CD7 antibody in T cells is high, the CD7 antibody is injected into a mouse tumor model, and the lifetime of mice can be prolonged; t cells transfected by the T cell transfecting agent have high killing efficiency on HELA cells and LOVO cells.
Owner:SHANDONG RES INST OF ADULT CELL IND TECH CO LTD

Preparation method and application of single-chain antibody fragment targeting SARS-COV-2 nucleocapsid protein

Disclosed are a preparation method and application of a single-chain antibody fragment targeting SARS-COV-2 nucleocapsid protein, aiming to provide a single-chain antibody fragment with high affinity and strong specificity. The present disclosure obtains three single-chain antibody fragments targeting SARS-COV-2 nucleocapsid protein through construction of a nanobody phage library and phage screening technology. The single-chain antibody fragment consists of a heavy chain variable region, a 15aa connecting peptide, and a light chain variable region connected in sequence, and has an amino acid sequence shown in SEQ ID NO: 1-SEQ ID NO: 3. The single-chain antibody fragment in the present disclosure has excellent binding performance and specificity with the SARS-COV-2 nucleocapsid protein, can be applied to a variety of immunoassay platforms of the SARS-COV-2, and has broad application prospects in the field of SARS-COV-2 detection.
Owner:NANJING UNIV

MiRNA-SNPs fluorescence sensor based on programmable nuclease activity of PfAgo protein and sensing method and application of miRNA-SNPs fluorescence sensor

The invention discloses a miRNA-SNPs fluorescent sensor based on PfAgo protein programmable nuclease activity and a sensing method and application of the miRNA-SNPs fluorescent sensor. The fluorescent sensor comprises a chain A, a chain B, SplintR ligase, FQ and PfAgo nuclease. The chain A and the chain B generate a chain AB complementary to the miRNA to be detected through a base complementary pairing principle and the action of SplintR ligase; the AB chain excites PfAgo nuclease to perform targeted cleavage on an FQ single chain, so that a fluorophore FAM on the FQ single chain is separated from a quenching group BHQ1. According to the sensor and the sensing method thereof disclosed by the invention, zero background and accurate quantification of miRNA with mutated single basic group can be realized. The invention provides a simple, rapid and ultra-sensitive miRNA-SNPs accurate quantification strategy, and provides a powerful and universal detection platform for prognosis of human cancers related to miRNA related single nucleotide polymorphism.
Owner:NANJING NORMAL UNIVERSITY

Reagent for detecting avian leukosis virus, nano-enzyme immunochromatography test strip and application of nano-enzyme immunochromatography test strip

ActiveCN120741854AImmunoglobulins against virusesBiological testingLeucosisAvian leukosis viruses
The invention provides a reagent for detecting avian leukosis virus, a nano-enzyme immunochromatography test strip and application of the nano-enzyme immunochromatography test strip, and belongs to the technical field of immunology. Aiming at the problems that the existing avian leukosis virus detection method is complicated in operation, time-consuming or strong in equipment dependence, the reagent comprises a capture antibody and a detection antibody; a heavy chain variable region of the monoclonal antibody A comprises an amino acid sequence as shown in SEQ ID NO: 1, and a light chain variable region of the monoclonal antibody A comprises an amino acid sequence as shown in SEQ ID NO: 2; a heavy chain variable region of the monoclonal antibody B comprises an amino acid sequence as shown in SEQ ID NO: 5, and a light chain variable region of the monoclonal antibody B comprises an amino acid sequence as shown in SEQ ID NO: 6; the antigen binding fragment is a Fab fragment, an F (ab) 2 fragment or a single-chain Fv fragment. The reagent is mainly used for detecting avian leukosis virus, and is suitable for detecting samples such as cloaca swab, meconium, egg white or serum of poultry.
Owner:INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI +1

Antibodies that bind tnfrsf25

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.
Owner:SHATTUCK LABS INC

Methods for expanding t cells

This disclosure relates methods for expanding γδ T cells. More specifically, the disclosure relates to methods of expanding γδ T cells that have an eliminated or reduced expression of endogenous MHC Class I molecules, by expressing a single-chain fusion HLA Class I protein. In some embodiments, the endogenous B2M gene of the γδ T cells is disrupted. In some embodiments, the single-chain fusion HLA Class I protein includes at least a portion of B2M protein and at least a portion of HLA-E heavy chain.
Owner:NANJING LEGEND BIOTECH CO LTD +1

Epcam antibody and Epcam-CAR-T cells

The present invention is directed to a humanized monoclonal anti-human EpCAM antibody, such as a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 2 and VL having the amino acid of SEQ ID NO: 4. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.
Owner:PROMAB BIOTECH +1

Application of anti-PTPRZ1 chimeric antigen receptor macrophage in lung cancer treatment

The invention relates to application of anti-PTPRZ1 chimeric antigen receptor macrophages in lung cancer treatment, and belongs to the technical field of tumor targeted therapy. The invention constructs a novel chimeric antigen receptor (CAR) which comprises a coding sequence of a single-chain variable region fragment for specifically recognizing PTPRZ1, and a coding sequence of a CD8TM transmembrane region and a coding sequence of a CD3zeta intracellular signal transduction structural domain. The design ingeniously endows the chimeric antigen receptor (CAR) with high specificity, so that the chimeric antigen receptor (CAR) can accurately recognize and firmly bind to the surface of a tumor cell expressing PTPRZ1 protein. According to the present invention, the chimeric antigen receptor targeting PTPRZ1 is successfully transfected into the human macrophage to form the CAR-M. A flow cytometry verifies that compared with non-transfected macrophages (Mphi) or transfected macrophages lacking a specific target binding domain (CAR-M-delta), the CAR-M has the advantage that the efficiency of swallowing PTPRZ1 positive tumor cells is remarkably improved in the aspect of the efficiency of swallowing PTPRZ1 positive tumor cells. Therefore, the CAR-M constructed by the invention can be used as a potential treatment means for targeting PTPRZ1 expression tumors.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

Bispecific antibody and application thereof

The invention relates to the technical field of biology, in particular to a bispecific antibody and application thereof. The invention provides a bispecific antibody which has neutralizing activity on an SARS-CoV-2 mutant strain (VOCs) and an SARS-related coronavirus (SARSr-CoVs), and the bispecific antibody is constructed by fusing single-chain variable fragments of the two antibodies through a GS linker. The bispecific antibody shows high binding capacity to S1, and has broad-spectrum and efficient activity to pseudovirus SARS-CoV-2 variants and SARS-related coronaviruses, so that the bispecific antibody provided by the invention has the potential of preventing and treating the SARS-CoV-2 and the SARS-related coronaviruses.
Owner:SUN YAT SEN UNIV

CD8 antibody modified anti-TIM-3 lipid nanoparticle, preparation method and application thereof

The invention provides a CD8 antibody modified anti-TIM-3 lipid nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of medical preparations. The lipid nanoparticle contains a chimeric antigen receptor; the chimeric antigen receptor comprises a single-chain antibody TIM-3; the nucleic acid artificial sequence of the single-chain antibody TIM-3 is as shown in SEQ ID NO. 5. According to the application, sequence optimization is carried out on a TIM-3 target spot, a CAR structure connected with a double-stimulating factor and a suicide gene is prepared, and anti-TIM-3 nano-lipid particles modified by a CD8 antibody are constructed and delivered into cells, so that CD8 + T cells can be effectively captured in a body, CAR-T cells can be generated, a complex process of in-vitro preparation is omitted, and the application has the advantages of simplicity, convenience in operation and high efficiency. The activation degree of T cells is improved while the antigen is efficiently recognized, the efficient anti-tumor effect is achieved, the survival time of breast cancer mice is obviously prolonged, and the growth of tumors is inhibited.
Owner:SHANDONG RES INST OF ADULT CELL IND TECH CO LTD